Pfizer is preparing to file its COVID-19 vaccine after a trial reached the safety milestone required by US regulators for emergency use, according to press reports.
Boehringer Ingelheim and South Korea’s Bridge Biotherapeutics have decided to axe their collaboration over a potential new drug for idiopathic pulmonary fibrosis (IPF), BBT-877.
Swedish biotech Calliditas has announced plans to file its rare disease drug Nefecon with the FDA early next year following positive results from a phase 3 clinical trial.
